Greer Provides Extract for Duke University Study Evaluating Sublingual-Oral Immunotherapy for Peanut Allergies.LENOIR, N.C. -- Greer, a leading developer and provider of allergy immunotherapy products and source materials Noun 1. source materials - publications from which information is obtained source - a document (or organization) from which information is obtained; "the reporter had two sources for the story" , is providing peanut extract to Duke University Medical Center for their sublingual-oral immunotherapy study. The study is designed to evaluate whether sublingual-oral immunotherapy with an extract from raw peanut source materials is a safe and effective treatment for children and adults with peanut allergies. Wesley Burks (http://www.dukemednews.org/experts/detail.php?id=352), M.D., chief of the division of pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. allergy and immunology at Duke University Medical Center, is the principle investigator for the study which is being funded through a grant from the National Institutes of Health. "Greer was able to provide the peanut extract we needed for the two-year duration of the Duke study," says Dr. Burks. "I have worked with Greer in the past on research initiatives and once again the company was very helpful in supplying the materials we needed to launch the study." Nearly three million Americans are allergic to peanuts and brief or accidental contact with peanuts kills hundreds of people each year. The goal of the Duke study is to determine whether exposing participants to peanuts, by giving them small drops of peanut extract under the tongue, will make them less sensitive to the allergen allergen /al·ler·gen/ (al´er-jen) an antigenic substance capable of producing immediate hypersensitivity (allergy).allergen´ic pollen allergen . "This is an exciting milestone and marks a major step in the study of peanut allergies," says Dr. Robert Esch, Greer executive Vice President of Research & Development. "Dr. Burks' research will address the need for well-controlled, long-term trials for specific oral tolerance induction in food allergy food allergy Allergy medicine A condition, the incidence of which–0.3-7.5%–is obscured by controversial data and differing disease definitions; food-induced reactions of immediate-hypersensitivity type are common and include anaphylaxis, angioedema, . His work represents a promising approach for treating food allergies Food Allergies Definition Food allergies are the body's abnormal responses to harmless foods; the reactions are caused by the immune system's reaction to some food proteins. and improving the quality of life of peanut-allergic patients." The study is another example of Greer's ongoing role in providing pharmaceutical and biotech companies, as well as medical institutions, the allergenic extracts and source materials needed for drug development and research initiatives. Greer's Source Materials Business Unit specializes in supplying allergenic Allergenic A substance capable of causing an allergic reaction. Mentioned in: Echinococcosis source materials, such as pollens, dust mites, animal danders and molds and also provides allergenic extracts in a variety of formsCofreeze-dried or liquid intermediatesCoformulated to satisfy customer-defined specifications. Greer is currently involved in Phase IIB IIB Institute for Independent Business IIB Institute of International Business IIB Institute of International Bankers IIB International Investment Bank IIB Indian Institute of Banking & Finance IIB Included in Bankruptcy IIB Ice, Ice, Baby clinical trials for administering its standardized short ragweed ragweed, any plant of the genus Ambrosia, coarse, weedy herbs belonging to the family Asteraceae (aster family), most of which are native to America. They have inconspicuous greenish flowers and soft subdivided leaves. extract sublingually. Earlier this year, Greer presented findings of its Phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I at the 2006 American Academy The American Academy in Berlin is a non-partisan academic institution in Berlin. It was founded in September 1994 by a group of prominent Americans and Germans, among them Richard Holbrooke, Henry Kissinger, Richard von Weizsäcker, Fritz Stern and Otto Graf Lambsdorff and opened in of Allergy Asthma and Immunology Annual Meeting. For more information on the Duke peanut study, contact Pam Steele at 919-681-2949 or at foodallergy@mc.duke.edu. To learn more about Greer's Source Materials Business Unit or R&D efforts regarding sublingual-oral immunotherapy, visit www.greerlabs.com. About Greer: Greer is a leading developer and provider of allergy immunotherapy products and services for treating humans and animals. Greer's highly skilled scientists provide technical support for customers by continuing to focus on improving the lives of allergic patients. Greer's clinical development programs are focused on expanding the use of immunotherapy through oral administration of allergy immunotherapy. Greer's goal is to establish efficacy for standardized products which will be studied through clinical trials. The company was founded in 1904 and is located in Lenoir, N.C. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion